Securities code: 000919 securities abbreviation: Jinling Pharmaceutical Company Limited(000919) Announcement No.: 2022-015 Jinling Pharmaceutical Company Limited(000919) announcement on the progress of litigation involving the company
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Jinling Pharmaceutical Company Limited(000919) (hereinafter referred to as ” Jinling Pharmaceutical Company Limited(000919) ” or “the company”) disclosed on October 15, 2020, July 30, 2021 and August 14, 2021 that Huzhou Guoxin Materials Co., Ltd. (hereinafter referred to as “Guoxin materials”) and Chen Guoqiang sued the company, the judgment of first instance and the appeal to the people’s Court of Wuxing District, Huzhou City, Zhejiang Province on the ground of contract dispute. For details of the above matters, please refer to the announcement of Jinling Pharmaceutical Company Limited(000919) on litigation involving the company (Announcement No.: 2020-047) disclosed by the company in China Securities Journal, securities times, Shanghai Securities News and cninfo.com on October 15, 2020, July 30, 2021 and August 14, 2021 Announcement Jinling Pharmaceutical Company Limited(000919) on the progress of the company’s litigation (Announcement No.: 2021-039) and announcement Jinling Pharmaceutical Company Limited(000919) on the progress of the company’s litigation (Announcement No.: 2021-042). The relevant progress is hereby announced as follows:
1、 Progress of this lawsuit
Recently, the company received the civil judgment (2021) zhe 05 min Zhong No. 1401 made by the intermediate people’s Court of Huzhou City, Zhejiang Province (hereinafter referred to as “Huzhou intermediate people’s court”). The judgment made by Huzhou intermediate people’s court is as follows: reject Guoxin materials and Chen Guoqiang’s appeal and uphold the original judgment; The case acceptance fee of the second instance is 111800 yuan, which shall be borne by Guoxin materials and Chen Guoqiang; This judgment is final.
2、 Other undisclosed litigation and arbitration matters
(I) for the small amount litigation and arbitration matters that have not been disclosed before the disclosure of this announcement, except for the litigation cases that have been disclosed by the company, the company (including the holding subsidiaries, the same below) does not have other litigation and arbitration matters that have cumulatively met the disclosure standards.
(II) as of the date of this announcement, the company has no other major litigation and arbitration matters that should be disclosed but have not been disclosed.
3、 Possible impact of the lawsuit announced this time on the company’s current profit or future profit
The result of this judgment will not have a significant impact on the company’s current or future profits, but will have a significant impact on the company’s lawsuit against Guoxin materials Chen Guoqiang’s equity transfer dispute has had a positive impact (for details, see the announcement on litigation matters related to performance commitment compensation of holding subsidiaries (Announcement No.: 2021-025) disclosed by the company in China Securities Journal, securities times, Shanghai Securities News and cninfo.com on March 31, 2021).
Please pay attention to investment risks.
4、 Documents for future reference
Civil judgment.
It is hereby announced.
Jinling Pharmaceutical Company Limited(000919) board of directors January 27, 2002
